EE41 Cost-Effectiveness of Anti-BCMA CAR T-Cell Therapy in Triple-Class Refractory Multiple Myeloma
Jul 1, 2022, 00:00 AM
10.1016/j.jval.2022.04.293
https://www.valueinhealthjournal.com/article/S1098-3015(22)00494-6/fulltext
Section Title :
Section Order :
10258
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00494-6&doi=10.1016/j.jval.2022.04.293